The Nevro HFX solution provides substantial, long-lasting relief for people suffering from chronic pain and painful diabetes-related neuropathy using mild electrical pulses to interrupt the transmission of pain signals to the brain, alleviating pain and improving quality of life. HFX includes spinal cord stimulation and support services to provide relief of pain, burning, tingling, and numbness. A one-week temporary trial is used to determine if HFX is right for each patient. 9 out of 10 people who complete an HFX trial choose to move forward with treatment.[1]

The HFX Solution has been proven to be safe and effective and has been used to treat over 70,000 patients. It is the most studied SCS therapy available.

- **About 75%** of people with back and leg pain on 10 kHz therapy sustained significant pain relief at 24 months in a randomized clinical trial[2]
- **74%** of people with back and leg pain patients treated with Nevro 10 kHz therapy achieved pain relief as validated by real-world in 1,660 patients[3]
- **86%** of people with painful diabetic neuropathy experienced substantial, long-term relief at 12 months[3]
- **77%** average pain relief for painful diabetic neuropathy[4]
- **68%** of people with painful diabetic neuropathy reported improved neurological function, including motor strength, reflexes, and function[4]

The studies cited above are referenced below.

In November of 2021, Nevro presented a trio of publications in top tier Diabetes Journals (Diabetes Care and the Journal of Diabetes, Science and Technology) demonstrated the durability and real-world application of Nevro's 10 kHz Therapy in the treatment of painful diabetic neuropathy (PDN):

1. *Durability of high-frequency 10 kHz spinal cord stimulation for patients with painful diabetic neuropathy refractory to conventional treatments.* Senza PDN 12-month data demonstrates durable results of 86% responder rate, 77% average pain relief and 68% neurologic improvement (up from 62%) within the original 10 kHz arm and comparable results in the CMM cross over arm. (**Diabetes Care**)

2. *A real-world analysis of high-frequency 10 kHz spinal cord stimulation for the treatment of painful diabetic peripheral neuropathy.* A real-world analysis of PDN patients from HFX Cloud data showing an average 79.5% responder rate. Patients included in the analysis had an average time of 21.8 months post-implant. (**The Journal of Diabetes Science and Technology** (**JDST**))

3. *Neuromodulation in the Treatment of Painful Diabetic Neuropathy: A Review of Evidence for Spinal Cord Stimulation.* A comparative literature review that evaluated current evidence for both high-frequency and low-frequency SCS to treat PDN. The analysis concluded that high-frequency (10 kHz) SCS offers several advantages over low-frequency, paresthesia-dependent SCS, including greater pain relief, a higher proportion of patients achieving treatment success, paresthesia-free, and evidence of improved neurological function. (**JDST**)